JP2002502810A5 - - Google Patents

Download PDF

Info

Publication number
JP2002502810A5
JP2002502810A5 JP2000530194A JP2000530194A JP2002502810A5 JP 2002502810 A5 JP2002502810 A5 JP 2002502810A5 JP 2000530194 A JP2000530194 A JP 2000530194A JP 2000530194 A JP2000530194 A JP 2000530194A JP 2002502810 A5 JP2002502810 A5 JP 2002502810A5
Authority
JP
Japan
Prior art keywords
epothilone
lyophilized composition
infusion
solution
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000530194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002502810A (ja
JP4644364B2 (ja
Filing date
Publication date
Priority claimed from GBGB9802451.6A external-priority patent/GB9802451D0/en
Priority claimed from GBGB9813646.8A external-priority patent/GB9813646D0/en
Application filed filed Critical
Priority claimed from PCT/EP1999/000702 external-priority patent/WO1999039694A2/en
Publication of JP2002502810A publication Critical patent/JP2002502810A/ja
Publication of JP2002502810A5 publication Critical patent/JP2002502810A5/ja
Application granted granted Critical
Publication of JP4644364B2 publication Critical patent/JP4644364B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000530194A 1998-02-05 1999-02-03 エポシロン組成物 Expired - Fee Related JP4644364B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9802451.6A GB9802451D0 (en) 1998-02-05 1998-02-05 Organic compounds
GB9802451.6 1998-02-05
GB9813646.8 1998-06-24
GBGB9813646.8A GB9813646D0 (en) 1998-06-24 1998-06-24 Organic compounds
PCT/EP1999/000702 WO1999039694A2 (en) 1998-02-05 1999-02-03 Compositions containing organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009278624A Division JP2010090147A (ja) 1998-02-05 2009-12-08 エポシロン組成物

Publications (3)

Publication Number Publication Date
JP2002502810A JP2002502810A (ja) 2002-01-29
JP2002502810A5 true JP2002502810A5 (cg-RX-API-DMAC7.html) 2006-03-30
JP4644364B2 JP4644364B2 (ja) 2011-03-02

Family

ID=26313062

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000530194A Expired - Fee Related JP4644364B2 (ja) 1998-02-05 1999-02-03 エポシロン組成物
JP2009278624A Pending JP2010090147A (ja) 1998-02-05 2009-12-08 エポシロン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009278624A Pending JP2010090147A (ja) 1998-02-05 2009-12-08 エポシロン組成物

Country Status (36)

Country Link
US (5) US20030203876A1 (cg-RX-API-DMAC7.html)
EP (1) EP1052974B1 (cg-RX-API-DMAC7.html)
JP (2) JP4644364B2 (cg-RX-API-DMAC7.html)
KR (3) KR20080016756A (cg-RX-API-DMAC7.html)
CN (2) CN100396276C (cg-RX-API-DMAC7.html)
AR (1) AR017979A1 (cg-RX-API-DMAC7.html)
AT (1) ATE431733T1 (cg-RX-API-DMAC7.html)
AU (1) AU753519B2 (cg-RX-API-DMAC7.html)
BE (1) BE1012140A3 (cg-RX-API-DMAC7.html)
BR (1) BR9907647B1 (cg-RX-API-DMAC7.html)
CA (1) CA2320182C (cg-RX-API-DMAC7.html)
CL (1) CL2003002786A1 (cg-RX-API-DMAC7.html)
CO (1) CO4920246A1 (cg-RX-API-DMAC7.html)
CY (1) CY1109311T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303168B6 (cg-RX-API-DMAC7.html)
DE (1) DE69940904D1 (cg-RX-API-DMAC7.html)
DK (1) DK1052974T3 (cg-RX-API-DMAC7.html)
ES (1) ES2324378T3 (cg-RX-API-DMAC7.html)
FR (1) FR2774909B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0101564A3 (cg-RX-API-DMAC7.html)
ID (1) ID26549A (cg-RX-API-DMAC7.html)
IL (2) IL137550A0 (cg-RX-API-DMAC7.html)
IT (1) IT1313549B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA00007681A (cg-RX-API-DMAC7.html)
MY (1) MY125921A (cg-RX-API-DMAC7.html)
NO (2) NO329376B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ506389A (cg-RX-API-DMAC7.html)
PE (1) PE20000272A1 (cg-RX-API-DMAC7.html)
PL (1) PL201329B1 (cg-RX-API-DMAC7.html)
PT (1) PT1052974E (cg-RX-API-DMAC7.html)
RU (1) RU2214246C2 (cg-RX-API-DMAC7.html)
SI (1) SI1052974T1 (cg-RX-API-DMAC7.html)
SK (2) SK287487B6 (cg-RX-API-DMAC7.html)
TR (1) TR200002299T2 (cg-RX-API-DMAC7.html)
TW (1) TW457095B (cg-RX-API-DMAC7.html)
WO (1) WO1999039694A2 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
ATE267197T1 (de) 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
GB9802451D0 (en) * 1998-02-05 1998-04-01 Ciba Geigy Ag Organic compounds
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
SK8552003A3 (en) 2001-01-25 2004-06-08 Bristol Myers Squibb Co Parenteral formulation containing epothilone analogs
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
CA2434526C (en) * 2001-01-25 2011-11-01 Bristol Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
DE60225666T2 (de) 2001-01-25 2009-04-16 Bristol-Myers Squibb Co. Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EE200300397A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaadid refraktaarsete kasvajate raviks
IL156988A0 (en) 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
ATE554756T1 (de) 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
EP1372650B1 (en) * 2001-03-19 2008-11-19 Novartis AG Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US6800653B2 (en) 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2003235761A1 (en) 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US20050271669A1 (en) * 2002-06-10 2005-12-08 Hohneker John A Combinations comprising epothilones and pharmaceutical uses thereof
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
HRP20050278A2 (en) 2002-09-23 2005-10-31 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
JP2006504743A (ja) 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤
ES2279139T3 (es) * 2002-10-15 2007-08-16 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Uso de los derivados de epotilona para el tratamiento del hiperparatiroidismo.
ATE452888T1 (de) 2002-11-07 2010-01-15 Kosan Biosciences Inc Trans-9,10-dehydroepothilon c und d, analoga davon und verfahren zu deren herstellung
KR20060122819A (ko) * 2003-10-09 2006-11-30 코산 바이오사이언시즈, 인코포레이티드 치료학적 제형
CN1867343A (zh) * 2003-10-09 2006-11-22 高山生物科学股份有限公司 治疗制剂
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7655442B2 (en) 2004-01-29 2010-02-02 Eisai R&D Management Co., Ltd. Method for stabilizing macrolide compounds
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN100409846C (zh) * 2005-11-22 2008-08-13 菏泽睿鹰制药集团有限公司 一种埃坡霉素b脂质体制剂及应用
CN101506217B (zh) 2006-08-16 2012-09-05 诺瓦提斯公司 埃坡霉素b的晶型及在药物组合物中的用途
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
CN101642453B (zh) * 2009-09-15 2011-03-16 湖南迪诺制药有限公司 一种含有埃坡霉素b的药物制剂
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
ES3024636T3 (en) * 2017-09-27 2025-06-04 Novartis Ag Parenteral formulation comprising siponimod

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IL27947A (en) * 1967-05-09 1972-07-26 Weitzman J Method for the production of thermoplastic resin particles and of mixtures of such particles with additives
JPS56115855A (en) * 1980-02-19 1981-09-11 Toyota Motor Corp Method and apparatus for controlling ignition timing of engine
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
JPH0753396A (ja) * 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物,その製造法および用途
CA2092271C (en) * 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
DE59609305D1 (de) * 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs

Similar Documents

Publication Publication Date Title
AU753519B2 (en) Compositions containing organic compounds
TW201008594A (en) Stable pharmaceutical formulations
JPH0611700B2 (ja) アントラサイクリングリコシド含有薬学的組成物
US6683100B2 (en) Organic compounds
EP4061333B1 (en) Injectable compositions of ursodeoxycholic acid
AU2019373373A1 (en) Cyclodextrin-based formulation of a Bcl-2 inhibitor
KR890000907B1 (ko) 안정한 현탁액 제조용 고체 약물 제형의 제조방법
US6818662B2 (en) Pharmaceutical composition
CA3117511C (en) Cyclodextrin-based formulation of a bcl-2 inhibitor
RU2804366C2 (ru) Состав ингибитора bcl-2 на основе циклодекстрина
ES2324376T3 (es) Formulaciones farmaceuticas para administracion parenteral que comprenden epotilona.
HK1047227A1 (zh) 具有改進藥理學性質的非腸胃道使用的雌莫司汀磷酸鹽製劑
KR860000512B1 (ko) 페니실린 유도체의 동결 건조물로 된 주사용량 단위물 제조방법
EA044714B1 (ru) Состав ингибитора bcl-2 на основе циклодекстрина
OA20228A (en) Cyclodextrin-based formulation of A BCL2 inhibitor.
HK1105808B (en) Pharmaceutical formulations for parenteral administration comprising epothilone
KR20090106666A (ko) 유기화합물 함유 조성물
OA16267A (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same.